Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry

Jorge Labrador, David Martinez-Cuadron, Cristina Gil, Mar Tormo, Josefina Serrano, Pilar Martinez Sanchez, Eduardo Rodríguez-Arbolí, Jose-Mario Mariz, Fernanda Trigo, Teresa Bernal Del Castillo, Juan Miguel Bergua Burgues, Carlos Rodríguez-Medina, Olga Salamero, Joana Brioso Infante, Juan Manuel Alonso-Dominguez, Pilar Herrera Puente, María Luz Amigo, Susana Vives, Raimundo García-Boyero, Lorenzo Algarra, Mercedes Colorado, Monica Romero, Claudia Sossa, Maria Vidriales Vicente, Armando Mena Duran, Celina Benavente, Esperanza Lavilla-Rubira, Maria Jose Sayas Lloris, Emília Cortesão, Veronica Lizama, Olga Arce-Fernández, María García-Fortes, Maria Dolores Madrigal, Manuel Perez Encinas, Marta Valero-Nuñez, Luis Felipe Casado Montero, Maria Teresa Olave Rubio, Ágata Almela, Diana Cuervo, Victor Noriega Concepción, Marcela Espinoza, Beatriz De Rueda Ciller, Manuel Barrios García, Rosa Fernández, Bernardo González González, Carmen Montes, Christine Rojas, Esther Pérez-Santaolalla, María Lourdes Amador Barciela, ANA Yurena Oliva Hernandez, Rebeca Rodriguez-Veiga, Isabel Cano, Evelyn Acuña-Cruz, Antonio Solana-Altabella, Pau Montesinos

Blood (2025) 146 (Supplement 1): 875.

https://doi.org/10.1182/blood-2025-875

Published: 2025

Journal Articles

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Bruno Paiva, Leire Burgos, Carmen Gonzalez, Rebeca Rodriguez Veiga, Antonio Solana-Altabella, Pilar Lloret-Madrid, Evelyn Acuña-Cruz, Cristina Gil, Carmen Botella, Eduardo Rodríguez-Arbolí, Teresa Caballero, Teresa Bernal Del Castillo, Maria Teresa Cedena Romero, Pilar Herrera Puente, Claudia Sossa, Josefina Serrano, Joaquín Sánchez-García, José Luis López Lorenzo, María-Belén Vidriales, Mar Tormo, Monica Romero, Mercedes Colorado, Celina Benavente, Juan Miguel Bergua Burgues, Manuel Pérez-Encinas, Lorenzo Algarra, Carlos Rodríguez-Medina, Dolly Viviana Fiallo Suarez, Raimundo García-Boyero, Luis Felipe Casado Montero, Jorge Labrador, Manuel Barrios García, Beatriz De Rueda Ciller, Marcela Espinoza, Maria Jose Sayas Lloris, Diana Cuervo, María Luz Amigo, Jose-Mario Mariz, Karoll Giovanna Gomez Correcha, Carmen Couto, Esther Perez, Ágata Almela, Susana Vives, Esperanza Lavilla-Rubira, Olga Arce-Fernández, Maria Teresa Olave Rubio, Miguel Lopez, Maria Dolores Madrigal, Lara María Gómez García, Sofia Grille, Sebastián Hidalgo, Daniel García Belmonte, Maria Jose Garcia, Maria Del Carmen Martinez Chamorro, Olga Salamero, Amparo Sempere, Beatriz Martín Herreros, Armando Mena Duran, David Martinez-Cuadron, Pau Montesinos

Blood (2025) 146 (Supplement 1): 5293.

https://doi.org/10.1182/blood-2025-5293

Published: 2025

Journal Articles

Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial

Blood (2025) 146 (Supplement 1): 1694.

https://doi.org/10.1182/blood-2025-1694

Published: 2025

Journal Articles

Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry

Blood (2025) 146 (Supplement 1): 40.

https://doi.org/10.1182/blood-2025-40

Published: 2025

Journal Articles

Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 4328.

https://doi.org/10.1182/blood-2024-203076

Published: 2024

Journal Articles

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Blood (2024) 144 (Supplement 1): 2874.

https://doi.org/10.1182/blood-2024-200280

Published: 2024

Journal Articles

A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial

Blood (2023) 142 (Supplement 1): 2960.

https://doi.org/10.1182/blood-2023-189676

Published: 2023

Journal Articles

Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

Olga Salamero, Tim C.P Somervaille, Antonieta Molero, Evelyn Acuña-Cruz, Jose A. Perez-Simon, Rosa Coll, Montserrat Arnan, Brayan Merchan, Ana Perez, Isabel Cano, Rebeca Rodríguez-Veiga, Mabel Arevalo, Sonia Gutierrez, Carlos Buesa, Douglas V Faller, Francesc Bosch, Pau Montesinos

Blood (2022) 140 (Supplement 1): 1711–1713.

https://doi.org/10.1182/blood-2022-168945

Published: 2022

Journal Articles

Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Blood (2022) 140 (Supplement 1): 8919–8920.

https://doi.org/10.1182/blood-2022-162591

Published: 2022

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Blood (2021) 138 (Supplement 1): 1307.

https://doi.org/10.1182/blood-2021-150281

Published: 2021

Journal Articles

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Olga Salamero, Tim C.P Somervaille, Antonieta Molero, Evelyn Acuña-Cruz, Jose Pérez-Simón, Rosa Coll, Montserrat Arnan Sangerman, Brayan Merchan, Ana Perez, Isabel Cano, Rebeca Rodríguez-Veiga, Sonia Gutierrez, Carlos Buesa, Francesc Bosch, Pau Montesinos

Blood (2021) 138 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2021-152183

Published: 2021

Journal Articles

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2021) 138 (Supplement 1): 1284.

https://doi.org/10.1182/blood-2021-146666

Published: 2021

Journal Articles

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2021) 138 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2021-146681

Published: 2021

Journal Articles

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136957

Published: 2020

Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-139903

Published: 2020

Journal Articles

Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates

Joaquin Martinez-Lopez, MD PhD, Pau Montesinos, MD PhD, Pilar Martinez Sanchez, Julian Gorrochategui, Jose Luis Rojas, Daniel Primo, PhD, Juan-Miguel Bergua, MD, Rosa M M. Ayala, MD PhD, Maria Calbacho, MD, Nieves López-Muñoz, Evelyn Acuña, MD, Jose Antonio Pérez-Simón, MD, Adolfo de la Fuente, Jaime Perez De Oteyza, MDPhD, Rebeca Rodríguez-Veiga, MD, Blanca Boluda, Isabel Cano, MD, Joan Ballesteros, PhD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-134336

Published: 2020

Journal Articles

Robust Efficacy Signals in Elderly AML Patients Treated with Iadademstat in Combination with Azacitidine (ALICE Phase IIa Trial)

Olga Salamero, MD, Tim C.P Somervaille, PhD FRCP, FRCPath, Antonieta Molero, MD, Evelyn Acuña, MD, Ana Perez, MD, Isabel Cano, MD, Rebeca Rodríguez-Veiga, MD, Sonia Gutierrez, Roger Bullock, MD, Carlos Buesa, PhD, Francesc Bosch, MD PhD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-134310

Published: 2020

Journal Articles

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Blood (2019) 134 (Supplement_1): 2584.

https://doi.org/10.1182/blood-2019-125683

Published: 2019

Journal Articles

Liposomal Doxorubicin in Aggressive B Cell Lymphoma Has Similar Efficacy to the Conventional Formulation: Results from a Retrospective Cohort Study

Evelyn Acuña Cruz, MD, Jimena Cannata Ortiz, MD, Ana García-Noblejas, MD, Adrian Alegre, Reyes Arranz Sáez, MD

Blood (2015) 126 (23): 5106.

https://doi.org/10.1182/blood.V126.23.5106.5106

Published: 2015

Journal Articles

Comparison of Assesment of Imaging Response with Magnetic Resonance (MR) and 18 fdg-PET/TC in Multiple Myeloma (MM). Single Centre Experience

Adrian Alegre, Beatriz Aguado, Miriam González-Pardo, Evelyn Acuña, Álvaro Arriero, Maria Aragonés, Lourdes Del Campo, S Llorente, Elena Ocón, Nieves Gómez León

Blood (2014) 124 (21): 5707.

https://doi.org/10.1182/blood.V124.21.5707.5707

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial

Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry

Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial

Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates

Robust Efficacy Signals in Elderly AML Patients Treated with Iadademstat in Combination with Azacitidine (ALICE Phase IIa Trial)

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Liposomal Doxorubicin in Aggressive B Cell Lymphoma Has Similar Efficacy to the Conventional Formulation: Results from a Retrospective Cohort Study

Comparison of Assesment of Imaging Response with Magnetic Resonance (MR) and 18 fdg-PET/TC in Multiple Myeloma (MM). Single Centre Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only